Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 13, 2023

SELL
$176.32 - $240.22 $12,342 - $16,815
-70 Reduced 3.5%
1,930 $419,000
Q1 2023

May 11, 2023

SELL
$161.33 - $204.36 $2,581 - $3,269
-16 Reduced 0.79%
2,000 $363,000
Q4 2022

Feb 08, 2023

SELL
$191.53 - $236.82 $7,661 - $9,472
-40 Reduced 1.95%
2,016 $396,000
Q3 2022

Oct 17, 2022

SELL
$123.79 - $277.42 $540,590 - $1.21 Million
-4,367 Reduced 67.99%
2,056 $462,000
Q2 2022

Jul 13, 2022

BUY
$93.97 - $143.33 $399,466 - $609,295
4,251 Added 195.72%
6,423 $812,000
Q1 2022

May 12, 2022

BUY
$98.9 - $132.37 $10,384 - $13,898
105 Added 5.08%
2,172 $275,000
Q3 2021

Nov 02, 2021

BUY
$101.2 - $125.87 $1,518 - $1,888
15 Added 0.73%
2,067 $252,000
Q2 2021

Aug 10, 2021

BUY
$107.45 - $135.95 $6,876 - $8,700
64 Added 3.22%
2,052 $233,000
Q1 2021

May 07, 2021

SELL
$95.46 - $133.08 $4,773 - $6,654
-50 Reduced 2.45%
1,988 $239,000
Q4 2020

Feb 04, 2021

BUY
$75.23 - $109.23 $153,318 - $222,610
2,038 New
2,038 $207,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.